Traditional MedicareCoverageMedium impact
Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms
Medicare/CMS - LCD·Oncology, Hematology·Local Coverage Determination
Effective date
May 15, 2026
We identified it
Jun 17, 2026
Summary
This is a new Local Coverage Determination (LCD) for genomic sequence analysis panels used in treating solid organ cancers, effective May 15, 2026. The policy establishes coverage criteria and billing guidelines for genetic testing in cancer treatment through National Government Services Medicare contractor.
Action Required
By May 15, 2026: Billing team must review the full LCD L37810 policy at the CMS Medicare Coverage Database to identify specific CPT codes, coverage criteria, and documentation requirements for genomic sequence analysis panels in solid organ cancer treatment. Update billing system with any prior authorization requirements and coverage limitations. Train clinical staff on documentation requirements for genetic testing claims.